Gizem Ayna Duran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gizem Ayna Duran has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Yağmur Kiraz
Department of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Izmir, Türkiye
2 shared publications - Başak Özay
İzmir University of Economics
1 shared publication - Berkcan Dogan
Department of Medical Genetics, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Turkey
1 shared publication Berna Ayar
1 shared publication- Bilge Sezin Akkoç
Izmir Ekonomi Universitesi
1 shared publication - Caner Günaydın
Department of Pharmacology, School of Medicine, Samsun University, Samsun, Turkey
1 shared publication
Latest Publications
- 20 March 2026
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 38 (1) , 118-137
LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis
Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most commonly diagnosed, and both present with distinct proteinopathies and progressive neuronal loss. Studies have implicated autophagy dysfunction as a common mechanism in both diseases. Therefore, the primary objective of our study is to use bioinformatics techniques to identify commonly upregulated genes associated with autophagy and apoptosis in AD and PD and to develop novel therapeutic agents targeting these genes. Using publicly available transcriptomic data (GSE5281 and GSE48350 for AD; GSE49036 for PD), differentially expressed genes (DEGs) are identified and restricted to autophagy and apoptosis related genes compiled from the Human Autophagy Database. According to our results, the genes CARD8, FXN, LAMP2, EVI2B, MYOT, P2RX7, and MEGF10 are consistently upregulated in both conditions, while ELAPOR1 is downregulated. Our PPI network analysis results highlight LAMP2 as a central molecule regulating lysosomal-autophagic fusion. Gene enrichment analyses implicate pathways involved in autophagy, lysosomal activity, and inflammation. Drug repurposing analysis using the DSigDB database on the Enrichr platform has shown that the histone deacetylase (HDAC) inhibitors Vorinostat (suberoylanilide hydroxamic acid, SAHA), Trichostatin A (TSA), and Valproic Acid (VPA) stand out as promising agents that may regulate this common gene network. These findings provide a number of autophagy- and apoptosis-related targets and therapies with the potential to address shared pathological features of AD and PD.
- 20 March 2026
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 38 (1) , 118-137
LAMP2-Centered Autophagy Network and HDAC Inhibitors as Therapeutic Leads in Alzheimer’s and Parkinson’s Diseases: A Bioinformatic Analysis
Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most commonly diagnosed, and both present with distinct proteinopathies and progressive neuronal loss. Studies have implicated autophagy dysfunction as a common mechanism in both diseases. Therefore, the primary objective of our study is to use bioinformatics techniques to identify commonly upregulated genes associated with autophagy and apoptosis in AD and PD and to develop novel therapeutic agents targeting these genes. Using publicly available transcriptomic data (GSE5281 and GSE48350 for AD; GSE49036 for PD), differentially expressed genes (DEGs) are identified and restricted to autophagy and apoptosis related genes compiled from the Human Autophagy Database. According to our results, the genes CARD8, FXN, LAMP2, EVI2B, MYOT, P2RX7, and MEGF10 are consistently upregulated in both conditions, while ELAPOR1 is downregulated. Our PPI network analysis results highlight LAMP2 as a central molecule regulating lysosomal-autophagic fusion. Gene enrichment analyses implicate pathways involved in autophagy, lysosomal activity, and inflammation. Drug repurposing analysis using the DSigDB database on the Enrichr platform has shown that the histone deacetylase (HDAC) inhibitors Vorinostat (suberoylanilide hydroxamic acid, SAHA), Trichostatin A (TSA), and Valproic Acid (VPA) stand out as promising agents that may regulate this common gene network. These findings provide a number of autophagy- and apoptosis-related targets and therapies with the potential to address shared pathological features of AD and PD.
- Open Access
- 10 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-16
LEP and FOXO1 genes, as a proposed tumor suppressor autophagic cell death related genes, can be targeted by antidiabetic therapy in nondiabetic breast cancer patients
Introduction Breast cancer can be treated effectively with personalized, gene-targeted therapies due to its molecular and genetic differences. Our study aims to identify breast cancer-specific tumor suppressor genes related to autophagic cell death and discover new drugs that target these mechanisms, even if they are not breast cancer-specific. Materials and methods Gene intensity values of 457 tumor and 19 healthy breast tissues were used to determine downregulated and upregulated genes related to autophagy and apoptosis using Bioconductor R program via LIMMA package. Then, genes affecting survival were identified by survival analysis via Kaplan-Meier Plotter tool. Furthermore, the signalling pathways associated with these genes and targeting candidate drug components were determined by gene enrichment analysis using “KEGG pathway option” and Drug MATADOR in “ShinyGo 0.82” web-tool, respectively. Results Breast cancer tumor tissues showed downregulation of genes related to autophagy and apoptosis (c19orf12, CRYAB, LEP, SRPX, SNCA, FOXO1) and upregulation of others (SLC7A5, ATP2A2, INHBA, ATP5IF1). Among these, SLC7A5, c19orf12, LEP, SPRX, SNCA, and FOXO1 affected patient survival and prognosis. The AMPK signaling pathway, targeting FOXO1 and LEP, was identified as key. Only the LEP gene was targeted by Metformin, Pioglitazone, Rosiglitazone, and Troglitazone. Conclusion In our study, survival associated LEP and FOXO1 genes were identified as candidate tumor suppressor genes associated with autophagic cell death in non-obese and non-diabetic breast cancer patients. Anti-diabetic drugs such as Metformin, Pioglitazone, Rosiglitazone, Troglitazone are proposed as candidate components in the treatment processes by targeting the LEP gene in nondiabetic breast cancer patients.
- 10 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-16
Open AccessLEP and FOXO1 genes, as a proposed tumor suppressor autophagic cell death related genes, can be targeted by antidiabetic therapy in nondiabetic breast cancer patients
Introduction Breast cancer can be treated effectively with personalized, gene-targeted therapies due to its molecular and genetic differences. Our study aims to identify breast cancer-specific tumor suppressor genes related to autophagic cell death and discover new drugs that target these mechanisms, even if they are not breast cancer-specific. Materials and methods Gene intensity values of 457 tumor and 19 healthy breast tissues were used to determine downregulated and upregulated genes related to autophagy and apoptosis using Bioconductor R program via LIMMA package. Then, genes affecting survival were identified by survival analysis via Kaplan-Meier Plotter tool. Furthermore, the signalling pathways associated with these genes and targeting candidate drug components were determined by gene enrichment analysis using “KEGG pathway option” and Drug MATADOR in “ShinyGo 0.82” web-tool, respectively. Results Breast cancer tumor tissues showed downregulation of genes related to autophagy and apoptosis (c19orf12, CRYAB, LEP, SRPX, SNCA, FOXO1) and upregulation of others (SLC7A5, ATP2A2, INHBA, ATP5IF1). Among these, SLC7A5, c19orf12, LEP, SPRX, SNCA, and FOXO1 affected patient survival and prognosis. The AMPK signaling pathway, targeting FOXO1 and LEP, was identified as key. Only the LEP gene was targeted by Metformin, Pioglitazone, Rosiglitazone, and Troglitazone. Conclusion In our study, survival associated LEP and FOXO1 genes were identified as candidate tumor suppressor genes associated with autophagic cell death in non-obese and non-diabetic breast cancer patients. Anti-diabetic drugs such as Metformin, Pioglitazone, Rosiglitazone, Troglitazone are proposed as candidate components in the treatment processes by targeting the LEP gene in nondiabetic breast cancer patients.
- 5 July 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (5) , 1-17
Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.
- 5 July 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (5) , 1-17
Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.
- Open Access
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 63-73
Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs - European Journal of Breast Health
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 63-73
Open AccessBioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs - European Journal of Breast Health
- Open Access
- 6 March 2024
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 11 (1) , 141-149
Kolanjiyokarsinom ve Hepatoselüler Karsinom Hastalarında Farklı Genler Tarafından Tetiklenen Ortak Biyolojik Yolaklar
Kolanjiyokarsinom (CHOL) erken teşhis edilmesi zor olan ve oldukça yüksek düzeyde öldürücü bir kanser türüdür. CHOL tanısında radyolojik görüntülemede kısıtlılıklar mevcuttur ve biyopsi ile tanı yöntemi gibi invaziv tanı yöntemleri dışında genetik tabanlı ve özgün biyobelirteçlerin belirlenmesi zorunlu hale gelmektedir. Literatürde bu amaçlar gerçekleştirilen çalışmalar çalışmalardan farklı olarak bizim çalışmamızda öncelikle intrahepatik (iCHOL) ve ekstrahepatik (eCHOL) kolanjiyokarsinom hastalarında ortak upregüle olan genler belirlenmiştir. Ayrıca çalışmamızda klinikte CHOL kanserlerinin LIHC kanserinden ayırt edici tanısının zor olması sebebiyle CHOL hastalarında hepatoselüler karsinomdan (LICH) farklı olarak ve LIHC hastaları ile ortak olarak upregüle edilen genlerin tespit edilmesi de amaçlanmıştır. Hastaların gen yoğunluk verileri NCBI Gene Expression Omnibus (GEO) veri tabanından (GSE121248, GSE132305 ve GSE45001) sağlanmıştır. Çalışmada R LIMMA paketinde yer alan lineer modelleme yöntemi kullanılarak kanserli olan ve olmayan örnekler arasında upregüle genler (differentially expressed genes-DEGs) tespit edilmiştir. Tespit edilen genlerin hangi biyolojik yolaklara etki ettiğini belirlemek için Gen seti zenginleştirme analizi (Fonksiyonel zenginleştirme analizi) (GSEA) ShinyGO 0.80 webtool kullanılarak yapılmıştır. Sonuçlarımıza göre CHOL hastalarında LIHC hastalarından farklı olarak upregüle edilen 4 gene (F2R, ITGA11, LAMC2 ve LAMB3) odaklanılmıştır. CHOL ve LIHC hastalarında ise ortak olarak upregüle edilen 2 gen (COL1A1, ITGA2) tespit edilmiştir. Söz konusu genlerinin ortak olarak işaret ettiği biyolojik yolaklar PI3K-Akt sinyal yolağı ve ekstraselüler matriks (ECM)-reseptör etkileşimi süreçleridir. Belirlenen genler ile protein-protein ve ilaç etkileşim çalışmaları sonuçları klinik denemeler ile desteklenip CHOL ile LIHC kanserlerinin ayırt edilmesinde etkin bir şekilde hedeflenebilecektir.
- 6 March 2024
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 11 (1) , 141-149
Open AccessKolanjiyokarsinom ve Hepatoselüler Karsinom Hastalarında Farklı Genler Tarafından Tetiklenen Ortak Biyolojik Yolaklar
Kolanjiyokarsinom (CHOL) erken teşhis edilmesi zor olan ve oldukça yüksek düzeyde öldürücü bir kanser türüdür. CHOL tanısında radyolojik görüntülemede kısıtlılıklar mevcuttur ve biyopsi ile tanı yöntemi gibi invaziv tanı yöntemleri dışında genetik tabanlı ve özgün biyobelirteçlerin belirlenmesi zorunlu hale gelmektedir. Literatürde bu amaçlar gerçekleştirilen çalışmalar çalışmalardan farklı olarak bizim çalışmamızda öncelikle intrahepatik (iCHOL) ve ekstrahepatik (eCHOL) kolanjiyokarsinom hastalarında ortak upregüle olan genler belirlenmiştir. Ayrıca çalışmamızda klinikte CHOL kanserlerinin LIHC kanserinden ayırt edici tanısının zor olması sebebiyle CHOL hastalarında hepatoselüler karsinomdan (LICH) farklı olarak ve LIHC hastaları ile ortak olarak upregüle edilen genlerin tespit edilmesi de amaçlanmıştır. Hastaların gen yoğunluk verileri NCBI Gene Expression Omnibus (GEO) veri tabanından (GSE121248, GSE132305 ve GSE45001) sağlanmıştır. Çalışmada R LIMMA paketinde yer alan lineer modelleme yöntemi kullanılarak kanserli olan ve olmayan örnekler arasında upregüle genler (differentially expressed genes-DEGs) tespit edilmiştir. Tespit edilen genlerin hangi biyolojik yolaklara etki ettiğini belirlemek için Gen seti zenginleştirme analizi (Fonksiyonel zenginleştirme analizi) (GSEA) ShinyGO 0.80 webtool kullanılarak yapılmıştır. Sonuçlarımıza göre CHOL hastalarında LIHC hastalarından farklı olarak upregüle edilen 4 gene (F2R, ITGA11, LAMC2 ve LAMB3) odaklanılmıştır. CHOL ve LIHC hastalarında ise ortak olarak upregüle edilen 2 gen (COL1A1, ITGA2) tespit edilmiştir. Söz konusu genlerinin ortak olarak işaret ettiği biyolojik yolaklar PI3K-Akt sinyal yolağı ve ekstraselüler matriks (ECM)-reseptör etkileşimi süreçleridir. Belirlenen genler ile protein-protein ve ilaç etkileşim çalışmaları sonuçları klinik denemeler ile desteklenip CHOL ile LIHC kanserlerinin ayırt edilmesinde etkin bir şekilde hedeflenebilecektir.
- 20 November 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (11) , 5851-5864
Pan-Cancer Analyses Identify the RRM2 Gene as a Biomarker with Diagnostic and Prognostic Roles in Multiple Human Cancers via Interactions with the hsa-let-7a-5p miRNA and EZH2
Background: Pan-cancer research has recently been conducted to identify genomic differences in multiple cancers compared with those in normal tissues. Our aims were to determine common differentially expressed genes (DEGs) by analysing the genomes of multiple cancers and to identify common cancer biomarkers for both diagnosis and treatment by determining the effect of these commonly changed genes on survival. Methods: We performed DEG and survival analyses by considering differences in expression levels in tumour and related normal tissues using the R programme and bioinformatic webtools Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, TIMER2.0, KM-plot, ShinyGO 0.77, miRTargetLink, and CancerMIRNome. Results: In our study, 5 genes (ribonucleotide reductase regulatory subunit M2 (RRM2), enhancer of the zeste homolog 2 (EZH2), Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), mitotic checkpoint serine/threonine kinase B (BUB1B), and centromere protein U (CENP-U)) were found to be upregulated in multiple cancers. Among these genes, the RRM2 gene was upregulated in more cancers and datasets. According to the gene enrichment analysis, the EZH2 gene also acted together with the RRM2 gene in terms of biological significance. Furthermore, instead of finding chemical agents that would inhibit the overexpression of both the RRM2 and EZH2 genes, miRNA screening targeting both genes were performed. As a result, hsa-let-7a-5p miRNA was found to have a strong interaction with both genes through the p53- and cell cycle-dependent pathways. Conclusion: The commonly upregulated RRM2 and EZH2 genes can be utilised as biomarkers for early diagnosis of multiple cancers. The joint interactions of the RRM2 and EZH2 genes with hsa-let-7a-5p may be a promising early treatment by inhibiting the expression levels of both genes by targeting hsa-let-7a-5p, an miRNA with low expression levels in cancers.
- 20 November 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (11) , 5851-5864
Pan-Cancer Analyses Identify the RRM2 Gene as a Biomarker with Diagnostic and Prognostic Roles in Multiple Human Cancers via Interactions with the hsa-let-7a-5p miRNA and EZH2
Background: Pan-cancer research has recently been conducted to identify genomic differences in multiple cancers compared with those in normal tissues. Our aims were to determine common differentially expressed genes (DEGs) by analysing the genomes of multiple cancers and to identify common cancer biomarkers for both diagnosis and treatment by determining the effect of these commonly changed genes on survival. Methods: We performed DEG and survival analyses by considering differences in expression levels in tumour and related normal tissues using the R programme and bioinformatic webtools Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, TIMER2.0, KM-plot, ShinyGO 0.77, miRTargetLink, and CancerMIRNome. Results: In our study, 5 genes (ribonucleotide reductase regulatory subunit M2 (RRM2), enhancer of the zeste homolog 2 (EZH2), Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), mitotic checkpoint serine/threonine kinase B (BUB1B), and centromere protein U (CENP-U)) were found to be upregulated in multiple cancers. Among these genes, the RRM2 gene was upregulated in more cancers and datasets. According to the gene enrichment analysis, the EZH2 gene also acted together with the RRM2 gene in terms of biological significance. Furthermore, instead of finding chemical agents that would inhibit the overexpression of both the RRM2 and EZH2 genes, miRNA screening targeting both genes were performed. As a result, hsa-let-7a-5p miRNA was found to have a strong interaction with both genes through the p53- and cell cycle-dependent pathways. Conclusion: The commonly upregulated RRM2 and EZH2 genes can be utilised as biomarkers for early diagnosis of multiple cancers. The joint interactions of the RRM2 and EZH2 genes with hsa-let-7a-5p may be a promising early treatment by inhibiting the expression levels of both genes by targeting hsa-let-7a-5p, an miRNA with low expression levels in cancers.
- 13 October 2022
- Published by Academician Publishing
Güncel Tıbbi Biyoloji ve Genetik Çalışmaları III
Akademisyen Yayınevi yöneticileri, yaklaşık 30 yıllık yayın tecrübesini, kendi tüzel kişiliklerine aktararak uzun zamandan beri, ticarî faaliyetlerini sürdürmektedir. Anılan süre içinde, başta sağlık ve sosyal bilimler, kültürel ve sanatsal konular dahil 2000 kitabı yayımlamanın gururu içindedir. Uluslararası yayınevi olmanın alt yapısını tamamlayan Akademisyen, Türkçe ve yabancı dillerde yayın yapmanın yanında, küresel bir marka yaratmanın peşindedir. Bilimsel ve düşünsel çalışmaların kalıcı belgeleri sayılan kitaplar, bilgi kayıt ortamı olarak yüzlerce yılın tanıklarıdır. Matbaanın icadıyla varoluşunu sağlam temellere oturtan kitabın geleceği, her ne kadar yeni buluşların yörüngesine taşınmış olsa da, daha uzun süre hayatımızda yer edineceği muhakkaktır. Akademisyen Yayınevi, kendi adını taşıyan “Bilimsel Araştırmalar Kitabı” serisiyle Türkçe ve İngilizce olarak, uluslararası nitelik ve nicelikte, kitap yayımlama sürecini başlatmış bulunmaktadır. Her yıl Mart ve Eylül aylarında gerçekleşecek olan yayımlama süreci, tematik alt başlıklarla devam edecektir. Bu süreci destekleyen tüm hocalarımıza ve arka planda yer alan herkese teşekkür borçluyuz.
- 13 October 2022
- Published by Academician Publishing
Güncel Tıbbi Biyoloji ve Genetik Çalışmaları III
Akademisyen Yayınevi yöneticileri, yaklaşık 30 yıllık yayın tecrübesini, kendi tüzel kişiliklerine aktararak uzun zamandan beri, ticarî faaliyetlerini sürdürmektedir. Anılan süre içinde, başta sağlık ve sosyal bilimler, kültürel ve sanatsal konular dahil 2000 kitabı yayımlamanın gururu içindedir. Uluslararası yayınevi olmanın alt yapısını tamamlayan Akademisyen, Türkçe ve yabancı dillerde yayın yapmanın yanında, küresel bir marka yaratmanın peşindedir. Bilimsel ve düşünsel çalışmaların kalıcı belgeleri sayılan kitaplar, bilgi kayıt ortamı olarak yüzlerce yılın tanıklarıdır. Matbaanın icadıyla varoluşunu sağlam temellere oturtan kitabın geleceği, her ne kadar yeni buluşların yörüngesine taşınmış olsa da, daha uzun süre hayatımızda yer edineceği muhakkaktır. Akademisyen Yayınevi, kendi adını taşıyan “Bilimsel Araştırmalar Kitabı” serisiyle Türkçe ve İngilizce olarak, uluslararası nitelik ve nicelikte, kitap yayımlama sürecini başlatmış bulunmaktadır. Her yıl Mart ve Eylül aylarında gerçekleşecek olan yayımlama süreci, tematik alt başlıklarla devam edecektir. Bu süreci destekleyen tüm hocalarımıza ve arka planda yer alan herkese teşekkür borçluyuz.
- Open Access
- 1 October 2022
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 16 (5) , 249-264
Autophagy-related genes affect the survival of multiple myeloma patients depending on chromosomal abnormality
Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status. Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN. Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan–Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways. Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A , FKBP1B , FOXO3 , and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering. Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.
- 1 October 2022
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 16 (5) , 249-264
Open AccessAutophagy-related genes affect the survival of multiple myeloma patients depending on chromosomal abnormality
Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status. Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN. Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan–Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways. Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A , FKBP1B , FOXO3 , and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering. Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.